GlassScriptPhysician profile
Michelle Irene Pego
NPI 1417493750
$4,468.27
in general payments reported to CMS, 2019-2025
29 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,004 · 2022: $617 · 2023: $959 · 2024: $811 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,847.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,129.36 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $878.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $330.53 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $301.70 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.81 | 2021-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $253.45 | 2023-2025 | |
| Astellas Pharma US INC | $231.16 | 2021-2025 | Veozah |
| Glaxosmithkline, LLC. | $214.06 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $140.86 | 2021 | |
| Phathom Pharmaceuticals, INC. | $96.07 | 2023-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $90.11 | 2021 | |
| Vanda Pharmaceuticals INC. | $76.64 | 2021-2022 | |
| Exact Sciences Corporation | $67.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $50.33 | 2022-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $47.85 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $34.00 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $32.73 | 2024 | |
| Mayne Pharma Commercial LLC | $32.22 | 2025 | |
| Daiichi Sankyo INC. | $29.41 | 2025 | Injectafer |
| Becton, Dickinson and Company | $25.74 | 2024 | Bd Max System, Bd Max Instrument |
| Otsuka America Pharmaceutical, INC. | $22.02 | 2025 | Rexulti |
| Exeltis, USA INC. | $20.38 | 2022 | |
| Agios Pharmaceuticals, INC. | $19.83 | 2025 | Pyrukynd |
| Sunovion Pharmaceuticals INC. | $19.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.51 | 2025 | |
| Seqirus USA INC | $14.49 | 2025 | Fluad, Flucelvax |
| Currax Pharmaceuticals LLC | $14.36 | 2024 | Contrave |
| Merck Sharp & Dohme LLC | $14.13 | 2023 | Dificid |
| Genentech USA, INC. | $10.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Pego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.